The expression of HLA-E and other IFN-γ related genes in MM highlights the presence of an immune phenotype in a proportion of patients with MM, which is further triggered and maintained by immunomodulatory drugs; CREB1 inhibition was able to exploit this phenotype potentiating the effect of pomalidomide in the presence of NK cells, without affecting NK cell viability. This evidence concerns the gene CREB1 and Miyoshi myopathy.